Home
ESPR
ESPR News

Latest Esperion Therapeutics Inc. (ESPR) News on February 5, 2025

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?

Zacks

22 days ago

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

GlobeNewswire

a month ago

Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a month ago

Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

2 months ago

Esperion Therapeutics Completes Financing Deals to Partially Repay Convertible Debt

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

GlobeNewswire

2 months ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

MT Newswires

2 months ago

Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target

MT Newswires

2 months ago

Esperion Swaps New Notes, Cash for $210 Million of Convertible Debt; Shares Slump Pre-Bell

Esperion Announces $210 Million Convertible Debt Financing

GlobeNewswire

2 months ago

Esperion Announces $210 Million Convertible Debt Financing

MT Newswires

2 months ago

Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

GlobeNewswire

2 months ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Zacks

2 months ago

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

MT Newswires

2 months ago

Esperion Therapeutics Files Applications for Non-Statin Medications in Canada

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

GlobeNewswire

2 months ago

Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk

MT Newswires

2 months ago

Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

GlobeNewswire

2 months ago

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

2 months ago

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

GlobeNewswire

3 months ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com

3 months ago

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Zacks

3 months ago

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

Zacks

3 months ago

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

3 months ago

Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

3 months ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

GlobeNewswire

3 months ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

3 months ago

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

GlobeNewswire

3 months ago

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Report Third Quarter 2024 Financial Results on November 7

GlobeNewswire

3 months ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings

GuruFocus.com

4 months ago

Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?

Insider Monkey

4 months ago

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

GlobeNewswire

4 months ago

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

Zacks

5 months ago

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

GlobeNewswire

5 months ago

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

GlobeNewswire

5 months ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

5 months ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Thomson Reuters StreetEvents

6 months ago

Q2 2024 Esperion Therapeutics Inc Earnings Call

MT Newswires

6 months ago

Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

Zacks

6 months ago

Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Zacks

6 months ago

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

6 months ago

Esperion Therapeutics: Q2 Earnings Snapshot

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

6 months ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Zacks

6 months ago

Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

6 months ago

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Esperion to Report Second Quarter 2024 Financial Results on August 12

GlobeNewswire

6 months ago

Esperion to Report Second Quarter 2024 Financial Results on August 12

Esperion to Participate in Upcoming BTIG Biotech Conference

GlobeNewswire

6 months ago

Esperion to Participate in Upcoming BTIG Biotech Conference

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

6 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

GlobeNewswire

7 months ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

MT Newswires

7 months ago

Esperion Therapeutics Enters $304.7 Million Royalty Purchase Agreement with OMERS; Shares Rise

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

BioPharma Dive

7 months ago

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

GlobeNewswire

7 months ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

Zacks

8 months ago

Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

8 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller

AFP

8 months ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up

AFP

8 months ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally

AFP

8 months ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

8 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

8 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

8 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

8 months ago

Best Date Night Fragrance in 2024

Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?

Zacks

8 months ago

Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?

Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?

Zacks

8 months ago

Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Zacks

8 months ago

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Esperion to Participate in Upcoming June Investor Conferences

GlobeNewswire

8 months ago

Esperion to Participate in Upcoming June Investor Conferences

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

GlobeNewswire

8 months ago

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

MT Newswires

9 months ago

Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

GlobeNewswire

9 months ago

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

GlobeNewswire

9 months ago

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Zacks

9 months ago

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript

Insider Monkey

9 months ago

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript

GuruFocus.com

9 months ago

Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

Benzinga

9 months ago

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

GuruFocus.com

9 months ago

Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase

MT Newswires

9 months ago

Top Premarket Gainers

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

Zacks

9 months ago

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

Associated Press Finance

9 months ago

Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Reports First Quarter 2024 Financial Results

GlobeNewswire

9 months ago

Esperion Reports First Quarter 2024 Financial Results

Esperion to Participate in Upcoming May Investor Conferences

GlobeNewswire

9 months ago

Esperion to Participate in Upcoming May Investor Conferences

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

9 months ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Esperion to Report First Quarter 2024 Financial Results on May 7

GlobeNewswire

9 months ago

Esperion to Report First Quarter 2024 Financial Results on May 7

11 Best Low Price Pharma Stocks To Invest In

Insider Monkey

9 months ago

11 Best Low Price Pharma Stocks To Invest In

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

GlobeNewswire

10 months ago

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

GlobeNewswire

10 months ago

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

Zacks

10 months ago

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

10 months ago

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

GlobeNewswire

10 months ago

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Business Wire

10 months ago

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

GlobeNewswire

10 months ago

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

GlobeNewswire

10 months ago

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

11 Best Small Cap Pharma Stocks to Invest In

Insider Monkey

a year ago

11 Best Small Cap Pharma Stocks to Invest In

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

Zacks

a year ago

Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics

5 Small Drug Stocks to Buy From a Rebounding Industry

Zacks

a year ago

5 Small Drug Stocks to Buy From a Rebounding Industry

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript

Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

Zacks

a year ago

Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues

Thomson Reuters StreetEvents

a year ago

Q4 2023 Esperion Therapeutics Inc Earnings Call

Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023

GuruFocus.com

a year ago

Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

Zacks

a year ago

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

a year ago

Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

a year ago

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

Share on Social Networks: